Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Siouve, Elise"'
Autor:
Orozco, Carolina T, Bersellini, Manuela, Irving, Lorraine M, Howard, Wesley W, Hargreaves, David, Devine, Paul WA, Siouve, Elise, Browne, Gareth J, Bond, Nicholas J, Phillips, Jonathan J, Ravn, Peter, Jackson, Sophie E
Publikováno v:
mAbs. 14
Although monoclonal antibodies have greatly improved cancer therapy, they can trigger side effects due to on-target, off-tumor toxicity. Over the past decade, strategies have emerged to successfully mask the antigen-binding site of antibodies, such t
Autor:
Dunsmore, Lavinia, Navo, Claudio D., Becher, Julie, de Montes, Enrique Gil, Guerreiro, Ana, Hoyt, Emily, Brown, Libby, Zelenay, Viviane, Mikutis, Sigitas, Cooper, Jonathan, Barbieri, Isaia, Lawrinowitz, Stefanie, Siouve, Elise, Martin, Esther, Ruivo, Pedro R., Rodrigues, Tiago, da Cruz, Filipa P., Werz, Oliver, Vassiliou, George, Ravn, Peter, Jiménez-Osés, Gonzalo, Bernardes, Gonçalo J. L., 0000-0002-9125-6081, 0000-0003-0161-412X, 0000-0002-8417-4475, 0000-0001-6940-8803, 0000-0003-0064-639X, 0000-0003-3035-8970, 0000-0002-5064-4379, 0000-0003-4337-8022, 0000-0003-0105-4337, 0000-0001-6594-8917
Publikováno v:
RIUR. Repositorio Institucional de la Universidad de La Rioja
instname
instname
Natural products that contain ortho-quinones show great potential as anticancer agents but have been largely discarded from clinical development because their redox-cycling behaviour results in general systemic toxicity. Here we report conjugation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e02248af381937f11f7cb1e3014d4e6a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Paula T. Hammond, Nisarg J. Shah, Kevin E. Shopsowitz, Michael J. Lee, Elise Siouve, Michael B. Yaffe, Stephen W. Morton, Erik C. Dreaden, Zhou J. Deng
Publikováno v:
PMC
Exposure to the EGFR (epidermal growth factor receptor) inhibitor erlotinib promotes the dynamic rewiring of apoptotic pathways, which sensitizes cells within a specific period to subsequent exposure to the DNA-damaging agent doxorubicin. A critical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::435d6f5c96fb67c988a1c5479ea3b2fb
https://orcid.org/0000-0002-9547-3251
https://orcid.org/0000-0002-9547-3251
Autor:
Dunsmore L; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK., Navo CD; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio-Bizkaia, Spain., Becher J; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK., de Montes EG; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK., Guerreiro A; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal., Hoyt E; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK., Brown L; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Zelenay V; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Mikutis S; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK., Cooper J; Wellcome-MRC Cambridge Stem Cell Institute, Department of Haematology, University of Cambridge, Cambridge, UK., Barbieri I; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK., Lawrinowitz S; Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany., Siouve E; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK., Martin E; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Ruivo PR; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal., Rodrigues T; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal., da Cruz FP; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK., Werz O; Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany., Vassiliou G; Wellcome-MRC Cambridge Stem Cell Institute, Department of Haematology, University of Cambridge, Cambridge, UK., Ravn P; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.; Department of Biotherapeutic Discovery, H. Lundbeck A/S, Valby, Denmark., Jiménez-Osés G; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio-Bizkaia, Spain. gjoses@cicbiogune.es.; Ikerbasque, Basque Foundation for Science, Bilbao, Spain. gjoses@cicbiogune.es., Bernardes GJL; Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK. gb453@cam.ac.uk.; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal. gb453@cam.ac.uk.
Publikováno v:
Nature chemistry [Nat Chem] 2022 Jul; Vol. 14 (7), pp. 754-765. Date of Electronic Publication: 2022 Jun 27.